

AMENDMENTS TO THE CLAIMS

Listing of the Claims:

1. (Previously Presented) A de-immunized anti-CD3 antibody, wherein one or more potential T cell epitopes are altered in at least one heavy chain or at least one light chain, wherein the potential T cell epitopes in the heavy chain are selected from the group consisting of residues 5, 11, 12-13, 20, 29, 38, 40, 61-68, 70, 81, 83-84, 87-88, 91, and 115 of SEQ ID NO: 10, and wherein the potential T cell epitopes in the light chain are selected from the group consisting of residues 10-11, 13, 18-19, 21, 29, 39, 41-42, 59-60, 62, 69, 75-77, 99, 103, and 106 of SEQ ID NO: 18.
2. (Previously Presented) A de-immunized anti-CD3 antibody of claim 1, wherein the heavy chain variable region comprises a sequence selected from the group consisting of SEQ. ID NOS: 11, 12, 13, 14, 15, 16 and 17.
3. (Previously Presented) A de-immunized anti-CD3 antibody of claim 1, wherein the light chain variable region comprises a sequence selected from the group consisting of SEQ. ID NOS: 19 and 20.
4. (Withdrawn) A method comprising: selecting an anti-CD3 antibody; and rendering the anti-CD3 antibody less immunogenic to a given species.
5. (Withdrawn) A method as in claim 4 wherein the step of rendering the anti-CD3 antibody less immunogenic to a given species comprises the steps of:
 - (a) determining at least part of the amino acid sequence of the antibody;
 - (b) identifying in the amino acid sequence one or more potential epitopes for T cells ("T cell epitopes") which are found in an endogenous protein of the given species; and
 - (c) modifying the amino acid sequence to eliminate at least one of the T cell epitopes identified in step (b) thereby to reduce the immunogenicity of the antibody or part thereof when exposed to the immune system of the given species.

6. (Canceled)
7. (Previously Presented) A pharmaceutical composition comprising a de-immunized anti-CD3 antibody of claim 1 and a pharmaceutically acceptable carrier.
8. (Original) A composition as in claim 7 wherein the de-immunized anti-CD3 antibody includes a heavy chain variable region comprising a sequence selected from the group consisting of SEQ. ID NOS: 11, 12, 13, 14, 15, 16 and 17.
9. (Original) A composition as in claim 7 wherein the de-immunized anti-CD3 antibody includes a light chain variable region comprising a sequence selected from the group consisting of SEQ. ID NOS: 19 and 20.
- 10-16. (Canceled)
17. (Withdrawn) Nucleic acid encoding a de-immunized anti-CD3 antibody.
18. (Withdrawn) Nucleic acid in accordance with claim 17 which encodes an antibody heavy chain variable region comprising a sequence selected from the group consisting of SEQ. ID NOS: 11, 12, 13, 14, 15, 16 and 17.
19. (Withdrawn) Nucleic acid in accordance with claim 17 which encodes an antibody light chain variable region comprising a sequence selected from the group consisting of SEQ. ID NOS: 19 and 20.
20. (Canceled)

21. (Previously Presented) A de-immunized anti-CD3 antibody comprising a heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NOs: 15, 16 and 17.
22. (Previously Presented) The de-immunized anti-CD3 antibody of claim 21, further comprising a light chain variable region comprising a sequence selected from the group consisting of SEQ ID NOs: 19 and 20.
23. (Previously Presented) The de-immunized anti-CD3 antibody of claim 21, wherein the antibody is a chimeric antibody.
24. (Previously Presented) The de-immunized anti-CD3 antibody of claim 23, wherein the chimeric antibody comprises a human constant region.
25. (Previously Presented) The de-immunized anti-CD3 antibody of claim 23, wherein the chimeric antibody comprises an engineered constant region comprising a portion of the human IgG2 constant region and a portion of the human IgG4 constant region.
26. (Previously Presented) The de-immunized anti-CD3 antibody of claim 21, wherein the de-immunized anti-CD3 antibody is a single chain antibody.
27. (Previously Presented) A pharmaceutical composition comprising a de-immunized anti-CD3 antibody of claim 21 and a pharmaceutically acceptable carrier.
28. (Previously Presented) A de-immunized anti-CD3 antibody heavy chain variable region comprising a sequence selected from the group consisting of SEQ ID NOs: 15, 16 and 17.
29. (Previously Presented) A de-immunized anti-CD3 antibody light chain variable region comprising a sequence selected from the group consisting of SEQ ID NOs: 19 and 20.

30. (New) The de-immunized anti-CD3 antibody of claim 1, wherein said antibody is a chimeric antibody comprising a human heavy chain constant region.
31. (New) The de-immunized anti-CD3 antibody of claim 21, wherein said antibody is a chimeric antibody comprising a human heavy chain constant region.